If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLPE.L Regulatory News (SLPE)

  • There is currently no data for SLPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Quarterly Investment Update at 30 June 2020

30 Sep 2020 07:00

RNS Number : 4793A
Standard Life Private Eqty Trst PLC
30 September 2020
 

Standard Life Private Equity Trust plc

Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13

 

1. Investment update for the quarter ended 30 June 2020

 

· The net asset value ("NAV") per ordinary share of Standard Life Private Equity Trust plc ("the Company") increased by 11.1% to 473.9 pence for the quarter ended 30 June 2020

· Realised gains and income on the portfolio during the quarter ended 30 June 2020 totalled £18.2 million (2.8% of NAV). The unrealised gain on a constant exchange rate basis was £46.3 million (7.1% of NAV). In addition, there were unrealised foreign exchange gains of £14.8 million (2.2% of NAV)

· The first interim dividend for the financial year ending 30 September 2020 of 3.3 pence per share was paid on 24 April 2020

· 100.0% by value of the portfolio was valued by the respective underlying managers at 30 June 2020

· NAV total return was 11.9% for the three months from 1 April 2020 to 30 June 2020

· Outstanding commitments were £465.5 million at 30 June 2020

· Cash and cash equivalents were £52.0 million at 30 June 2020

 

For the quarter ended 30 June 2020, the Company's NAV increased by 11.1% to 473.9 pence per share from 426.4 pence per share at 31 March 2020. At 30 June 2020, the Company's net assets were £728.6 million (31 March 2020 - £655.6 million). NAV total return was 11.9% for the three months from 1 April 2020 to 30 June 2020.

 

The closing value of the Company's portfolio, which included 63 private equity interests, was £660.9 million at 30 June 2020 (31 March 2020 - £580.3 million and 62 private equity interests). 100.0% by value of the portfolio valuations were dated 30 June 2020. The valuations by the underlying managers as at 30 June 2020 have not been adjusted by the Manager.

 

The total unrealised gain on the portfolio for the quarter ended 30 June 2020 was £61.1 million (9.3%), comprising £46.3 million (7.1%) of unrealised gain on a constant exchange rate basis and £14.8 million (2.2%) of unrealised foreign exchange gains. The capital movement of the FTSE All-Share Index (in sterling) was + 9.8% during the quarter. The unrealised foreign exchange gains were driven by the Euro and the US Dollar appreciating by 2.7% and 0.4% respectively relative to sterling over the quarter.

 

During the quarter ended 30 June 2020, the portfolio generated £30.0 million of distributions (quarter ended 31 March 2020 - £64.6 million). The Company funded £31.2 million of drawdowns (quarter ended 31 March 2020 - £44.0 million) into the portfolio. The portfolio distributions received during the quarter generated £18.2 million (2.8%) of net realised gains and income. This was equivalent to a return of 2.5 times the acquisition cost of the realised investments.

 

The Company made a new primary commitment during the quarter of €25.0 million to Vitruvian IV. The Company had total outstanding commitments to its 63 private equity interests of £465.5 million at 30 June 2020 (31 March 2020 - £451.2 million to 62 private equity interests). The Manager believes that around £68.3 million of the Company's outstanding commitments at 30 June 2020 are unlikely to be drawn.

 

The Company had cash and cash equivalents of £52.0 million at 30 June 2020 (31 March 2020 - £59.6 million). In addition, it is due £15.5 million (31 March 2020 - £15.2 million) of deferred consideration during the year from investments sold in 2019. The Company also had an undrawn £100.0 million syndicated revolving credit facility provided by Citi and Societe Generale, expiring in December 2024.

 

 

2. Activity since 30 June 2020

 

On 31 July 2020, the Company paid the second interim dividend for the year ending 30 September 2020 of 3.3 pence per ordinary share. The cost of the dividend was £4.9 million. In addition, the Company declared a third quarter dividend for the year ending 30 September 2020 of 3.3 pence per ordinary share, to be paid on 30 October, to shareholders on the Company's share register as at 25 September 2020.

 

During the period from 1 July 2020 to 14 September 2020 the Company received £16.4 million of distributions and funded £18.4 million of drawdowns and co-investment funding.

 

In August 2020, the Company made a $7.0 million co-investment into Visma, a leading provider of mission critical enterprise resource planning software in the Nordics and the Netherlands. The co-investment was made alongside Hg, Visma's lead investor.

 

The Company had cash and cash equivalents of £43.1 million at 14 September 2020. In addition, it is due £15.5 million of deferred consideration during the year from investments sold in 2019. The Company also had total outstanding commitments of £440.1 million. The Manager believes that around £66.3 million of the Company's outstanding commitments are unlikely to be drawn.

 

In September 2020, the syndicated revolving credit facility was expanded to £200.0 million from £100.0 million. This expansion of the existing facility includes the introduction of State Street Bank International as a new lender to the Company alongside long-term lenders Citi and Societe Generale. The expiry date of the facility remains as December 2024.

 

 

3. Update on COVID-19

 

The Manager continues to be mindful of the impact of COVID-19 and maintains regular communication with the private equity managers of the Company's investments. Whilst the Company's NAV has recovered strongly this quarter following a decline of 8.2% in Company NAV in March, the Manager remains cautious in respect of the valuation of the Company's portfolio in the coming quarters.

 

An update from the Manager, which provides responses to frequently asked questions in relation to COVID-19, is available within the Latest News section of the Company website; www.slpet.co.uk.

 

 

4. Future Announcements

 

The Company's estimated NAV at 31 August 2020 is also being announced today. The Company is expecting to announce its estimated NAV at 30 September 2020 on 14 October 2020.

 

It is anticipated that the Company will release its results for the year ending 30 September 2020 on or around 25 January 2021.

 

For further information please contact:-

 

Alan Gauld at SL Capital Partners LLP (0131 528 4424)

 

Note:-

Standard Life Private Equity Trust PLC is an investment company managed by SL Capital Partners LLP, the ordinary shares of which are admitted to listing by the UK Listing Authority and to trading on the Stock Exchange and which seeks to conduct its affairs so as to qualify as an investment trust under sections 1158-1165 of the Corporation Tax Act 2010. The Board of Standard Life Private Equity Trust PLC is independent of Standard Life Aberdeen plc and Phoenix Group Holdings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUKASRRUUKUAR
Date   Source Headline
4th Apr 202212:06 pmRNSChange of Name
22nd Mar 20222:14 pmRNSResult of AGM
21st Mar 202211:26 amRNSDirector Declaration
14th Mar 20225:30 pmRNSFTSE Russell Indices
14th Mar 20227:00 amRNSEstimated NAV at 28 February 2022
9th Mar 20222:07 pmRNSFirst Interim Dividend
24th Feb 20227:00 amRNSEdison review on Standard Life Private Equity Trst
14th Feb 20227:00 amRNSEstimated NAV at 31 January 2022
4th Feb 20223:24 pmRNSAnnual Report
1st Feb 202212:45 pmRNSDirector/PDMR Shareholding
27th Jan 20227:05 amRNSEstimated NAV at 31 December 2021
27th Jan 20227:00 amRNSAnnual Financial Report
6th Jan 20229:04 amRNSQuarterly disclosure
15th Dec 20217:00 amRNSEstimated NAV as at 30 November 2021
14th Dec 20213:48 pmRNSFourth Interim Dividend
6th Dec 20217:00 amRNSEdison review on Standard Life Private Equity Trst
12th Nov 20217:00 amRNSEstimated NAV at 31 October 2021
2nd Nov 20214:25 pmRNSDirector/PDMR Shareholding
14th Oct 20217:00 amRNSEstimated NAV at 30 September 2021
4th Oct 20214:15 pmRNSQuarterly disclosure
29th Sep 20217:02 amRNSEstimated NAV at 31 August 2021
29th Sep 20217:00 amRNSQuarterly Investment Update at 30 June 2021
17th Sep 20211:10 pmRNSUpdate research from QuotedData
7th Sep 20217:00 amRNSThird Interim Dividend
1st Sep 20217:00 amRNSDirectorate Change
16th Aug 202110:19 amRNSDirector/PDMR Shareholding
13th Aug 20217:00 amRNSEstimated NAV at 31 July 2021
10th Aug 20214:41 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
5th Aug 20213:32 pmRNSDirector/PDMR Shareholding
19th Jul 202111:58 amRNSEdison issues review on Standard Life Private
14th Jul 20219:05 amRNSDirector Declaration
14th Jul 20217:00 amRNSEstimated NAV at 30 June 2021
9th Jul 20213:29 pmRNSDoc re. Half yearly report
2nd Jul 20214:35 pmRNSQuarterly disclosure
29th Jun 20217:05 amRNSEstimated NAV at 31 May 2021
29th Jun 20217:00 amRNSHalf-year Report
14th Jun 20212:48 pmRNSSecond Interim Dividend
17th May 20217:00 amRNSEstimated NAV at 30 April 2021
12th May 20214:06 pmRNSDirector/PDMR Shareholding
27th Apr 202112:21 pmRNSDirector/PDMR Shareholding
22nd Apr 20217:05 amRNSEstimated NAV at 31 March 2021
22nd Apr 20217:00 amRNSQuarterly Investment Update at 31 December 2020
9th Apr 202111:58 amRNSHolding(s) in Company
6th Apr 20214:11 pmRNSQuarterly disclosure
23rd Mar 20211:50 pmRNSResult of AGM
12th Mar 20217:00 amRNSEstimated NAV as at 28 February 2021
8th Mar 20217:00 amRNSFirst Interim Dividend
25th Feb 20217:00 amRNSEdison review on Standard Life Private Eqty Trust
12th Feb 202110:22 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.